Telmisartan: Difference between revisions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) parser-claude batch MedTemplate pre-fill, Top 300 #184 |
MDElliottMD (talk | contribs) home-claude category backfill (parser-claude gap closure) |
||
| Line 21: | Line 21: | ||
== References == | == References == | ||
<references /> | <references /> | ||
[[Category:Angiotensin receptor blockers]] | |||
[[Category:Antihypertensives]] | |||
Latest revision as of 10:43, 23 May 2026
Telmisartan
Micardis
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Pharmacy
Starting dose
40 mg PO once daily; titrate to 80 mg
Preparations
20, 40, 80 mg tablets
US FDA Max
80 mg/d
Pharmacology
Routes
Oral
Onset
BP effect within 1-2 weeks
Duration
24 hours
Half-life
~24 hours (longest of the ARB class; suits patients with morning BP surge)[1]
Bioavailability
42-58% (oral; dose-dependent)[1]
Pregnancy
Contraindicated in pregnancy (all trimesters); fetal renal injury, oligohydramnios, hypocalvaria, hypotension. Stop on detection[1]
Legal status
Rx-only in US
Purported mechanism
Telmisartan is a selective AT1 angiotensin-II receptor antagonist with partial PPAR-γ agonism at therapeutic concentrations; the latter contributes to favorable metabolic effects (lipid handling, glucose tolerance) that distinguish it modestly within the ARB class.0 The 24-hour half-life supports once-daily dosing with consistent overnight BP control. Largely hepatically cleared (~98% biliary); no significant renal clearance dependence[1].
References
- ↑ 1.0 1.1 1.2 1.3 FDA Prescribing Information, Micardis (telmisartan), Boehringer Ingelheim, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020850s039lbl.pdf